Eli Lilly and Company (NYSE:LLY) Shares Down 2.2% – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares traded down 2.2% on Tuesday . The stock traded as low as $1,113.55 and last traded at $1,123.60. 2,272,672 shares changed hands during trading, a decline of 26% from the average session volume of 3,060,302 shares. The stock had previously closed at $1,149.36.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s Mounjaro received FDA approval to reduce heart-attack and stroke risk in certain adults with type 2 diabetes. The expanded indication could increase prescribing, strengthen Mounjaro’s competitive position and extend growth beyond blood-sugar control. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
• Positive Sentiment: Analyst coverage remains broadly favorable, with Wall Street’s average recommendation continuing to signal optimism toward LLY’s growth outlook. Wall Street Bulls Look Optimistic About Lilly
• Positive Sentiment: Lilly is expanding its neuroscience pipeline through internal development and acquisitions, potentially creating a longer-term growth engine alongside its diabetes and obesity portfolio. Analysts also see substantial opportunity in the company’s incretin drugs, including Zepbound and Mounjaro. Lilly Builds Neuroscience into a New Long-Term Growth Driver
• Neutral Sentiment: Recent acquisitions could diversify Lilly and support future growth, but investors must weigh the deals against integration costs, competition and time-limited patent protection for its leading GLP-1 medicines. Eli Lilly Has Been on an Acquisition Spree
• Negative Sentiment: Novartis’ failure in a closely watched cardiovascular trial damaged sentiment toward the broader Lp(a) cholesterol-drug class. Although Lilly was not the direct trial sponsor, investors appear concerned about cardiovascular pipeline risk and the broader healthcare sector sell-off. Eli Lilly Stock Falls on Competitor Novartis’ Cholesterol Drug Setback
• Negative Sentiment: Technical analysts cited a breakdown in key support levels, adding short-term pressure to LLY even as its long-term fundamentals remain strong. Why Is Eli Lilly Stock Falling Tuesday?

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on LLY shares. Citigroup lifted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Morgan Stanley reiterated an “overweight” rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, August 26th. Finally, Sanford C. Bernstein lifted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Stock Down 2.2%

The company has a market cap of $1.06 trillion, a P/E ratio of 37.70, a P/E/G ratio of 1.42 and a beta of 0.50. The company’s 50-day moving average is $1,190.13 and its two-hundred day moving average is $1,070.66. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last three months. Corporate insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Nykredit A S purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $392,919,000. Parkside Financial Bank & Trust lifted its holdings in shares of Eli Lilly and Company by 4.6% in the second quarter. Parkside Financial Bank & Trust now owns 8,108 shares of the company’s stock worth $9,725,000 after buying an additional 359 shares in the last quarter. MLG Wealth Management DBA Pine Grove Financial Group boosted its position in shares of Eli Lilly and Company by 10.4% during the second quarter. MLG Wealth Management DBA Pine Grove Financial Group now owns 677 shares of the company’s stock worth $810,000 after acquiring an additional 64 shares during the last quarter. Range Advisory LLC grew its stake in Eli Lilly and Company by 71.0% during the second quarter. Range Advisory LLC now owns 2,597 shares of the company’s stock valued at $3,115,000 after acquiring an additional 1,078 shares in the last quarter. Finally, Parrish Capital LLC purchased a new position in Eli Lilly and Company during the second quarter valued at $205,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.